RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION

Clinical trials for RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION explained in plain language.

Never miss a new study

Get alerted when new RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION trials appear

Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Cancer drug combo shows promise for patients with rare gene mutation

Disease control Terminated

This study tested two treatments—niraparib alone or niraparib plus bevacizumab—in people with recurrent endometrial or ovarian cancer that has a specific change in the ARID1A gene. The goal was to see how many patients' tumors shrank or disappeared. The study was stopped early af…

Matched conditions: RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION

Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control

Last updated Jun 11, 2026 12:12 UTC

RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION

Get alerted when new RECURRENT ENDOMETRIAL CANCER WITH ARID1A MUTATION trials appear

Cancer drug combo shows promise for patients with rare gene mutation